CLN-418 Study on Subjects With Advanced Solid Tumors

Exclusion Criteria

• •1. Prior used anti-B7H4 and/or anti-4-1BB antibody treatment.
• •2. Immuno-oncology therapy or targeted anti-cancer therapy within 4 weeks prior to first dose of investigational product, any other anti-cancer therapy within 2 weeks prior to first dose of investigational product.
• •3. Not yet recovered from surgery or (immune-related) toxicity related with previous treatment.
• •4. Known history or active infection of hepatitis B or C.
• •5. History of cirrhosis or non-alcohol steatohepatitis, alcohol or drug-related, autoimmune hepatitis.
• •6. Known brain metastases or other central nervous system metastases that are either symptomatic or untreated that require concurrent treatment.
• •7. Active infection that requires treatment with antibiotics or antiviral treatment within 3 weeks prior to first dose of investigational product.
• •8. Known history of infection with human immunodeficiency virus or known acquired immunodeficiency syndrome (AIDS).
• •9. Known autoimmune disease.
• •10. Clinically significant cardiac condition.
• •11. Pregnant or breastfeeding women.